Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 10, 2014 - Issue 2
Submit an article Journal homepage
1,460
Views
25
CrossRef citations to date
0
Altmetric
Case Report

Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy

Two case reports

Shiro Suzuki Department of Obstetrics and Gynecology; Nagoya University Graduate School of Medicine; Showa-ku, Nagoya JapanCorrespondence[email protected] [email protected]
,
Shiro Suzuki Department of Obstetrics and Gynecology; Nagoya University Graduate School of Medicine; Showa-ku, Nagoya JapanCorrespondence[email protected] [email protected]
,
Kiyosumi Shibata Department of Obstetrics and Gynecology; Nagoya University Graduate School of Medicine; Showa-ku, Nagoya Japan
,
Kiyosumi Shibata Department of Obstetrics and Gynecology; Nagoya University Graduate School of Medicine; Showa-ku, Nagoya Japan
,
Fumitaka Kikkawa Department of Obstetrics and Gynecology; Nagoya University Graduate School of Medicine; Showa-ku, Nagoya Japan
,
Fumitaka Kikkawa Department of Obstetrics and Gynecology; Nagoya University Graduate School of Medicine; Showa-ku, Nagoya Japan
,
Tetsuya Nakatsura Division of Cancer Immunotherapy; Exploratory Oncology Research and Clinical Trial Center; National Cancer Center; Kashiwa, Chiba Japan
&
Tetsuya Nakatsura Division of Cancer Immunotherapy; Exploratory Oncology Research and Clinical Trial Center; National Cancer Center; Kashiwa, Chiba Japan
 show all
Pages 338-343 | Received 11 Sep 2013, Accepted 15 Nov 2013, Published online: 21 Nov 2013

References

  • Kennedy AW, Biscotti CV, Hart WR, Webster KD. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989; 32:342 - 9; http://dx.doi.org/10.1016/0090-8258(89)90637-9; PMID: 2920955
  • Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000; 88:2584 - 9; http://dx.doi.org/10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5; PMID: 10861437
  • Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 2008; 109:370 - 6; http://dx.doi.org/10.1016/j.ygyno.2008.02.006; PMID: 18395777
  • Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 2007; 105:404 - 8; http://dx.doi.org/10.1016/j.ygyno.2006.12.024; PMID: 17292461
  • Takano M, Goto T, Kato M, Sasaki N, Miyamoto M, Furuya K. Short response duration even in responders to chemotherapy using conventional cytotoxic agents in recurrent or refractory clear cell carcinomas of the ovary. Int J Clin Oncol 2013; 18:556 - 7; http://dx.doi.org/10.1007/s10147-012-0404-x; PMID: 22552358
  • Kajiyama H, Shibata K, Mizuno M, Yamamoto E, Fujiwara S, Umezu T, Suzuki S, Nakanishi T, Nagasaka T, Kikkawa F. Postrecurrent oncologic outcome of patients with ovarian clear cell carcinoma. Int J Gynecol Cancer 2012; 22:801 - 6; http://dx.doi.org/10.1097/IGC.0b013e3182540145; PMID: 22617480
  • Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003; 306:16 - 25; http://dx.doi.org/10.1016/S0006-291X(03)00908-2; PMID: 12788060
  • Nakatsura T, Kageshita T, Ito S, Wakamatsu K, Monji M, Ikuta Y, Senju S, Ono T, Nishimura Y. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 2004; 10:6612 - 21; http://dx.doi.org/10.1158/1078-0432.CCR-04-0348; PMID: 15475451
  • Saikali Z, Sinnett D. Expression of glypican 3 (GPC3) in embryonal tumors. Int J Cancer 2000; 89:418 - 22; http://dx.doi.org/10.1002/1097-0215(20000920)89:5<418::AID-IJC4>3.0.CO;2-I; PMID: 11008203
  • Toretsky JA, Zitomersky NL, Eskenazi AE, Voigt RW, Strauch ED, Sun CC, Huber R, Meltzer SJ, Schlessinger D. Glypican-3 expression in Wilms tumor and hepatoblastoma. J Pediatr Hematol Oncol 2001; 23:496 - 9; http://dx.doi.org/10.1097/00043426-200111000-00006; PMID: 11878776
  • Aviel-Ronen S, Lau SK, Pintilie M, Lau D, Liu N, Tsao MS, Jothy S. Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol 2008; 21:817 - 25; http://dx.doi.org/10.1038/modpathol.2008.37; PMID: 18469798
  • Maeda D, Ota S, Takazawa Y, Aburatani H, Nakagawa S, Yano T, Taketani Y, Kodama T, Fukayama M. Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol 2009; 22:824 - 32; PMID: 19329941
  • Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, Yokomine K, Harao M, Beppu T, et al. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 2006; 12:2689 - 97; http://dx.doi.org/10.1158/1078-0432.CCR-05-2267; PMID: 16675560
  • Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, Mizuno S, Ishii H, Nakachi K, Konishi M, et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res 2012; 18:3686 - 96; http://dx.doi.org/10.1158/1078-0432.CCR-11-3044; PMID: 22577059
  • Leffers N, Daemen T, Helfrich W, Boezen HM, Cohlen BJ, Melief K, Nijman HW. Antigen-specific active immunotherapy for ovarian cancer. Cochrane Database Syst Rev 2010; 20:CD007287; PMID: 20091627
  • Suzuki S, Yoshikawa T, Hirosawa T, Shibata K, Kikkawa F, Akatsuka Y, Nakatsura T. Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma. Cancer Sci 2011; 102:622 - 9; http://dx.doi.org/10.1111/j.1349-7006.2011.02003.x; PMID: 21205085
  • Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30:2691 - 7; http://dx.doi.org/10.1200/JCO.2012.41.6750; PMID: 22614989

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.